Stay updated with breaking news from Ping Chua. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Insurers paid for the anti-parasite drug as a treatment for COVID despite a lack of evidence surrounding its effectiveness, according to a new study.
Insurers could prevent substantial waste by restricting prescription coverage for inappropriate use of ivermectin for COVID-19.
Claims data for private insurance and Medicare Advantage plans show spike in inappropriate ivermectin prescriptions for COVID-19.
THURSDAY, Jan. 20, 2022 (HealthDay News) -- Insurers could prevent substantial waste by restricting prescription coverage for inappropriate use of ivermectin for COVID-19, according to a research letter published online Jan. 13 in the Journal of the American Medical Association. Kao-Ping Chua, M.D., Ph.D., from University of Michigan Medical School in Ann Arbor, and colleagues
Insurers are heavily subsidizing the prescription drug ivermectin, despite studies finding it ineffective for treating COVID-19.